Femtobiomed works with Catholic hospital for joint research on cell therapies

By Lim Chang-won Posted : September 19, 2022, 13:38 Updated : September 19, 2022, 13:38

[Courtesy of Seoul St. Mary's Hospital]

SEOUL -- Femtobiomed, a developer of a cargo-free intracellular delivery platform in South Korea, has tied up with a Catholic University hospital to establish a mutual cooperation system for joint research on cell therapies and the development of anti-cancer immune cell therapies.

Cell therapy refers to placing new, healthy cells into the body to replace diseased or damaged ones, and modulating the function of the patient’s cells through the expression of factors or direct interaction, or the removal of disease-causing or dysfunctional cells using immune cells. Femtobiomed's cargo-free intracellular delivery platform called "Cell Shot" directly delivers desired genetic materials such as mRNA into target cells without using viruses in vitro.

"Through our cell shot real-time transfection process, which has established an unrivaled technology area for delivering various genetic materials including mRNA, we will make efforts to strengthen global competitiveness in the domestic cell therapy market," Femtobiomed CEO Lee Sang-hyeon said in a statement on September 19.

Cell Shot is an advanced nonviral delivery technology capable of injecting matters into cells that are aligned in series and pass one by one. "We have built a cell treatment facility, Good Manufacturing Practice (GMP), which is an essential facility for cell treatment and used it to conduct various immune cell therapy and stem cell research. We hope that cell therapy will be new hope for patients suffering from diseases," said Seoul St. Mary's Hospital head Yoon Seung-kew.

기사 이미지 확대 보기